Pfizer announced on Tuesday that the U.S. Food and Drug Administration (FDA) had granted priority review to the registration dossier for its cervical cancer treatment developed with Denmark's Genmab.

Tivdak is an antibody-conjugate for patients with recurrent or metastatic cervical cancer with disease progression during or after first-line chemotherapy.

The 'priority review' designation means that the FDA aims to rule on the application within six months, compared with ten months for a standard review.

In this case, the agency's final decision is expected in May.

Copyright (c) 2024 CercleFinance.com. All rights reserved.